A open and parallel-controlled study evaluating booster vaccination with either intramuscular injection or inhaled version of Convidecia
Latest Information Update: 15 Mar 2022
At a glance
- Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; Ad5-nCoV Tianjin CanSino Biotechnology (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
Most Recent Events
- 15 Mar 2022 New trial record
- 13 Mar 2022 According CanSino Biologics Inc media release, medRxiv published an academic paper on this study.
- 13 Mar 2022 Results published in the Media Release